Faculty of Pharmacy, University of Lisbon

Middle East Pharmaceutical Regulatory Affairs Training Course - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 4, 2023

She has worked in the pharmaceutical industry since 1988 for companies like MSD, SmithKline Beecham, Karl Engelhard and HEXAL where she has held the position of Regulatory Affairs Regional Manager, responsible for regulatory affairs and later on in commercial operations for countries in the Middle East and Africa.

Key Points: 
  • She has worked in the pharmaceutical industry since 1988 for companies like MSD, SmithKline Beecham, Karl Engelhard and HEXAL where she has held the position of Regulatory Affairs Regional Manager, responsible for regulatory affairs and later on in commercial operations for countries in the Middle East and Africa.
  • Heba has been working with Regulatory Affairs in the Middle East for more than 25 years.
  • For the past 20 years Heba held the position of Middle East & Africa Regulatory and Quality Head at different Pharmaceutical and Medical Device companies; Gambro, Bayer and Novo Nordisk.
  • Heba is now the Middle East and Africa Associate Director at PPD where she is providing regulatory consulting services and training to Health Care companies.

Medical Device Regulations in the Middle East and North Africa Training Course: Getting to Grips with a Fast Growing Market

Retrieved on: 
Monday, May 22, 2023

For the past 20 years Heba held the position of Middle East & Africa Regulatory and Quality Head at different Pharmaceutical and Medical Device companies; Gambro, Bayer and Novo Nordisk.

Key Points: 
  • For the past 20 years Heba held the position of Middle East & Africa Regulatory and Quality Head at different Pharmaceutical and Medical Device companies; Gambro, Bayer and Novo Nordisk.
  • Heba is now the Middle East and Africa Associate Director at PPD where she is providing regulatory consulting services and training to Health Care companies.
  • Between 2005 and August 2008 she was Regional Head, Middle East, for Sandoz International, Germany, responsible for all commercial and business development activities.
  • She spoke also for DIA (Drug Information Association) Switzerland on "Clinical Trials in the Middle East", DIA Europe Meeting, Geneva 2011.

CADTH Honours 2 Leaders for Outstanding Contributions to Health Technology Assessment in Canada

Retrieved on: 
Tuesday, May 16, 2023

OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.

Key Points: 
  • OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.
  • These prizes honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada's reputation for excellence in the field.
  • Brian was a key member of the international joint task group convened by the International Network of Agencies for Health Technology Assessment to lead this work.
  • Dr. Kednapa Thavorn is at the forefront of this advancement in Canada, as both a methodologist and health economist.

Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer

Retrieved on: 
Wednesday, April 19, 2023

Sandra Casaca has been appointed Chief Quality Officer of Alvotech and Sarah Tanksley will be joining the Board of Directors of Alvotech hf., the operating entity for Alvotech’s manufacturing site in Iceland.

Key Points: 
  • Sandra Casaca has been appointed Chief Quality Officer of Alvotech and Sarah Tanksley will be joining the Board of Directors of Alvotech hf., the operating entity for Alvotech’s manufacturing site in Iceland.
  • “I want to thank Sarah for her strong leadership and commitment to Alvotech.
  • Sandra is an accomplished quality executive with a demonstrated history of excellence in both drug development and commercial manufacturing operations in the U.S., Europe, Canada and Latin America.
  • She previously held senior leadership positions in quality at leading companies in the life sciences, including BMS, Amgen, AbbVie and Atara.

Henrique Cordeiro Joins Neology as Vice President of Business Development for North America

Retrieved on: 
Thursday, April 6, 2023

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- Neology today announced that Henrique Cordeiro had been appointed Vice President of Business Development for North America.

Key Points: 
  • SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- Neology today announced that Henrique Cordeiro had been appointed Vice President of Business Development for North America.
  • With over 15 years of experience in both consulting and business development, Cordeiro brings a unique passion to the table.
  • Combining his enthusiasm for leadership with success from prior projects, he has proven his ability to develop and expand business in critical markets.
  • "We look forward to growing our business under Henrique’s leadership," said Bradley H. Feldmann, Neology Chairman & CEO.

REGENCOR EXPANDS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
Wednesday, March 22, 2023

to its Scientific Advisory Board.

Key Points: 
  • to its Scientific Advisory Board.
  • He has worked with the FDA and is a consultant for the Endocrinologic and Metabolic Drugs Advisory Committee.
  • "Regencor is uniquely positioned to advance treatments for myocardial infarction and to help prevent the progression to heart failure."
  • "We are delighted and honored to have such accomplished scientific leaders join our Scientific Advisory Board," said Sean Edwards, Chief Executive Officer of Regencor.

Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts

Retrieved on: 
Thursday, December 8, 2022

He is also involved in clinical and translational research in the field of rare tumors and sarcomas.

Key Points: 
  • He is also involved in clinical and translational research in the field of rare tumors and sarcomas.
  • Professor Italiano graduated from the University of Nice, France, and completed a post-doctoral fellowship at Memorial Sloan Kettering Cancer Center, New York, US.
  • Co-Founder and Scientific Advisor of Surface Oncology and previously Scientific Advisor of Tarus Therapeutics, Professor Stagg is an internationally recognized expert working on identifying the mechanisms of immunosuppression.
  • Michel Bouvier, Chairman of Domain Therapeutics’ Scientific Advisory Board, commented: “As Domain moves towards the clinical phase to deliver differentiated GPCR-targeting immunotherapies for the precise treatment of cancer, it is great to see the strengthening of the Company’s Scientific Advisory Board with the addition of two highly distinguished scientists.

FSD Pharma Announces Changes to the Board of Directors

Retrieved on: 
Monday, November 28, 2022

Effective at the same time was the resignation of Fernando Cugliari from the Board of Directors.

Key Points: 
  • Effective at the same time was the resignation of Fernando Cugliari from the Board of Directors.
  • On behalf of FSD, I would like to thank Mr. Cugliari for his contributions to the Board.
  • FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development.
  • Forward-looking statements contained in this press release include statements relating to the future of FSD Pharma Inc. FSD Pharma cannot give any assurance that such forward-looking statements will prove to have been correct.

Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Retrieved on: 
Thursday, November 17, 2022

While L-Dopa remains the most effective pharmacotherapy for Parkinsons disease, the occurrence of LID is difficult to manage and drastically interferes with Parkinsons patients quality of life.

Key Points: 
  • While L-Dopa remains the most effective pharmacotherapy for Parkinsons disease, the occurrence of LID is difficult to manage and drastically interferes with Parkinsons patients quality of life.
  • This preclinical study showed that AV-101 reduced LID with no adverse effects of treatment, stated Shawn Singh, Chief Executive Officer of Vistagen.
  • Dr. Di Paolo has been at the forefront of research in neuropharmacology and treatments for Parkinsons disease for decades.
  • MPTP is a neurotoxin that kills dopaminergic neurons in the striatum, producing motor symptoms similar to those of PD.

Breakthrough RNA-Based Anti-Cancer Immunotherapy Treatments Being Developed by Global Consortium led by the Hadassah Cancer Research Institute

Retrieved on: 
Monday, September 19, 2022

JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.

Key Points: 
  • JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.
  • While RNA-based therapies, namely mRNA vaccines, shined during the pandemic and saved millions of lives, they have yet to be successfully tested in cancer therapies.
  • About the Hadassah Cancer Research Institute:
    Hadassah Cancer Research Institute (HCRI) is a translational research arm of Hadassah Medical Organization and Sharett Cancer Center in Jerusalem.
  • For additional information on the Hadassah Cancer Research Institute and CanceRNA, contact: